Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Consumers Want More Info from Drug Makers: JPMA Survey
November 18, 2002
- GSK Reports Results of Major Survey on COPD
November 18, 2002
- MPC: Merger Synergism Boosts Sales, Profits
November 18, 2002
- DIAGNOSTIC NEWS IN BRIEF
November 18, 2002
- Arrow Japan to Diversify Business from Critical Care Products
November 18, 2002
- Terumo: Sales Up 3.4% in Japan, 8.1% Overseas
November 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 18, 2002
- OTC NEWS IN BRIEF
November 18, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 18, 2002
- Kowa to Codevelop Arteriosclerosis Drugs with GENFIT of France
November 18, 2002
- REGULATORY NEWS IN BRIEF
November 18, 2002
- Market Must Be Attractive to Invite Investment from Abroad: JPMA President
November 18, 2002
- Bill for Law on IP Presented to Lower House
November 18, 2002
- Yamanouchi: Record-high Sales, Operating Profits Attributable to Harnal, Lipitor
November 18, 2002
- Drug Substitution by Pharmacists to Become Major Topic
November 18, 2002
- Eisai: Pariet, Aricept Contribute to Good Sales, Profits
November 18, 2002
- BUSINESS NEWS IN BRIEF
November 18, 2002
- Semi-annual Business Results
November 18, 2002
- WEBSITE NEWS
November 18, 2002
- Pramipexole Reported as 1st-Line Treatment for Parkinson's Disease
November 18, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…